Josh Nickols, PhD, MBA
Dr. Nickols is President and CEO of InvisionHeart and brings to the company 15 years of healthcare experience. Following the PhD program in Molecular Neuroscience and MBA from Vanderbilt University, Dr. Nickols joined BioMimetic Therapeutics where he led the development of the Sports Medicine department and therapeutics designed for the treatment of cartilage, tendon and ligament injuries. The program spanned research and design, product candidate testing in large animal models, and ultimately commercial development.
Later as Chief Technology Officer at Insight Genetics, Dr. Nickols led a portfolio of molecular assays for the detection of significant mutations in non-small cell lung cancer, principally Anaplastic Lymphoma Kinase and its role as predictive marker for treatment of patients with the target Pfizer drug, Crizotinib.
Dr. Nickols was most recently VP of Business Development at Device Innovation Group where he led the development of instruments and technologies to introduce new efficiencies in medicine. Within each role, Dr. Nickols drove translational programs bridging the development of clinical technology and medical needs.